Atea Pharmaceuticals annual stock-based compensation
2018
2019
2020
2021
2022
2023
2024
2025
Atea Pharmaceuticals Stock-Based Compensation Growth & History (AVIR)
Atea Pharmaceuticals's stock-based compensation was $20.7M for fiscal 2025.
View full Atea Pharmaceuticals company overviewAtea Pharmaceuticals annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $20.7M | −$31.0M | −59.97% |
| 2024 | 2024-12-31 | $51.8M | $2.3M | +4.73% |
| 2023 | 2023-12-31 | $49.4M | $2.7M | +5.80% |
| 2022 | 2022-12-31 | $46.7M | $7.1M | +17.91% |
| 2021 | 2021-12-31 | $39.6M | $32.2M | +431.33% |
| 2020 | 2020-12-31 | $7.5M | $6.8M | +1095.03% |
| 2019 | 2019-12-31 | $624,000 | $210,000 | +50.72% |
| 2018 | 2018-12-31 | $414,000 | — | — |
Atea Pharmaceuticals quarterly stock-based compensation
Q3.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $3.4M | −$1.3M | −27.56% |
| Q1 2026 | 2026-03-31 | $3.7M | −$3.2M | −46.35% |
| Q4 2025 | 2025-12-31 | $4.6M | −$9.7M | −67.93% |
| Q3 2025 | 2025-09-30 | $4.5M | −$7.6M | −62.87% |
| Q2 2025 | 2025-06-30 | $4.7M | −$8.1M | −63.31% |
| Q1 2025 | 2025-03-31 | $7.0M | −$5.6M | −44.77% |
| Q4 2024 | 2024-12-31 | $14.3M | $2.1M | +17.60% |
| Q3 2024 | 2024-09-30 | $12.2M | −$219,000 | −1.77% |
| Q2 2024 | 2024-06-30 | $12.7M | $367,000 | +2.97% |
| Q1 2024 | 2024-03-31 | $12.6M | $51,000 | +0.41% |
| Q4 2023 | 2023-12-31 | $12.2M | $512,000 | +4.40% |
| Q3 2023 | 2023-09-30 | $12.4M | $879,000 | +7.64% |
| Q2 2023 | 2023-06-30 | $12.4M | $445,000 | +3.74% |
| Q1 2023 | 2023-03-31 | $12.5M | $874,000 | +7.50% |
| Q4 2022 | 2022-12-31 | $11.6M | $294,000 | +2.59% |
| Q3 2022 | 2022-09-30 | $11.5M | $514,000 | +4.68% |
| Q2 2022 | 2022-06-30 | $11.9M | $1.9M | +19.00% |
| Q1 2022 | 2022-03-31 | $11.7M | $4.4M | +60.33% |
| Q4 2021 | 2021-12-31 | $11.4M | $8.5M | +302.38% |
| Q3 2021 | 2021-09-30 | $11.0M | $6.8M | +159.32% |
| Q2 2021 | 2021-06-30 | $10.0M | $9.8M | +4688.04% |
| Q1 2021 | 2021-03-31 | $7.3M | $7.1M | +3748.15% |
| Q4 2020 | 2020-12-31 | $2.8M | — | — |
| Q3 2020 | 2020-09-30 | $4.2M | $4.1M | +2599.36% |
| Q2 2020 | 2020-06-30 | $209,000 | — | — |
| Q1 2020 | 2020-03-31 | $189,000 | — | — |
| Q3 2019 | 2019-09-30 | $157,000 | — | — |
Atea Pharmaceuticals stock-based compensation trends
Over the last five fiscal years, Atea Pharmaceuticals's stock-based compensation increased from $7.5M to $20.7M, a change of $13.3M. The latest reported quarter, Q2 2026, shows $3.4M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Atea Pharmaceuticals source filings ↗